Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.
Details
Serval ID
serval:BIB_CF3AB1580107
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.
Journal
Current problems in dermatology
Publication state
Published
Issued date
2018
Peer-reviewed
Oui
Language
english
Pubmed
Publisher's website
Create date
27/08/2020 13:59
Last modification date
10/05/2022 5:36